The Atrial Natriuretic Peptide Receptor 2 pipeline drugs market research report outlays comprehensive information on the Atrial Natriuretic Peptide Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Atrial Natriuretic Peptide Receptor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Musculoskeletal Disorders, Hormonal Disorders, Undisclosed, and Oncology which include the indications Achondroplasia, Unspecified Musculoskeletal Disorders, Growth Disorders, Idiopathic Short Stature, Unspecified, and Non-Small Cell Lung Cancer. It also reviews key players involved in Atrial Natriuretic Peptide Receptor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Atrial Natriuretic Peptide Receptor 2 pipeline targets constitutes close to nine molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Preclinical, and Discovery stages are 1, 1, 4, and 3 respectively.
Atrial Natriuretic Peptide Receptor 2 overview
Atrial natriuretic peptide receptor 2 (NPR2), also known as guanylate cyclase B (GC-B), is a receptor protein that plays a crucial role in mediating the effects of atrial natriuretic peptide (ANP). The activation of NPR2 by ANP and the subsequent increase in cGMP levels have several physiological effects, including vasodilation (relaxation of blood vessels), natriuresis (excretion of sodium in urine), and diuresis (increased urine production). These effects contribute to the regulation of blood pressure and fluid balance.
For a complete picture of Atrial Natriuretic Peptide Receptor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
